Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Biosciences, Inc. on January 10, 2020. The report discloses a material event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Richard Scranton, M.D., resigned as Chief Medical Officer of the Company, effective January 24, 2020. Dr. Scranton is departing to pursue an opportunity at a private, early-stage biotechnology company. He will continue to serve as a consultant to the Company through March 31, 2020. A search for his replacement is currently underway.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the executive departure. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Richard Scranton, M.D., is resigning as Chief Medical Officer effective January 24, 2020.
- Dr. Scranton will remain as a consultant until March 31, 2020.
- The Company has initiated a search for a replacement Chief Medical Officer.
- No financial data or operational metrics are included in this specific filing.